NCT07275463

[99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression

SPECT/CT Imaging of Gastrin-releasing Peptide Receptor Expression in Breast Cancer With Different Estrogen Receptor Expression Using Technetium-99m-labelled DB8 [99mTc]Tc-DB8

• Status: Enrolling By Invitation
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences · Academic / Other
• Sex: Female
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The study should evaluate the \[99mTc\]Tc-DB8 accumulation in primary tumour of breast cancer patients with positive and negative estrogen receptor expression.

Detailed description

The aim of the study is to determine gastrin-releasing peptide receptor expression in primary breast cancer patients with positive and negative estrogen receptor expression before any systemic or local treatment. Phase II. Assessment of \[99mTc\]Tc-DB8 accumulation in primary tumors with positive and negative estrogen receptor expression in breast cancer patients.

Conditions

• Primary Breast Cancer

Interventions

Type	Name	Description
DRUG	[99mTc]Tc-DB8	One single injection of \[99mTc\]Tc-DB8, followed by SPECT/CT imaging 2 hours after the injection

Timeline

• Start date: 2025-10-01
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2025-12-10
• Last updated: 2025-12-22

Locations

1 site across 1 country: Russia